Groundbreaking Clinical Trial on Microdosing LSD and ADHD
A recent clinical trial has brought surprising insights into the effect of microdosing LSD on attention-deficit hyperactivity disorder (ADHD). With an increasing interest in the practice of psychedelic microdosing in wellness communities, this study examines its application for a specific condition, focusing on ADHD.
Microdosing refers to taking sub-perceptual doses of psychedelics, often LSD or psilocybin, in an attempt to enhance well-being and cognitive function without experiencing significant alterations in perception. This concept has gained traction over the past decade, although scientific research has lagged behind anecdotal reports.
The trial, conducted with 53 participants diagnosed with moderate to severe ADHD, divided the participants into two groups, with one group receiving 20 micrograms of LSD while the other received a placebo. All participants were administered doses twice a week over a six-week period.
At the end of the trial, both groups reported statistically significant reductions in ADHD symptoms. Interestingly, the placebo group exhibited slightly greater improvements, a difference deemed statistically insignificant.
Psychological Expectations and Trial Outcomes
Matthias Liechti, the study’s lead researcher, noted that the trial did not measure participants’ expectations about the efficacy of microdosing. However, most participants believed they received LSD, which Liechti points to as a factor enhancing the trial’s validity.
Liechti explained, ‘This is important as it points to a good blinding! There was absolutely no efficacy difference between placebo and LSD. Thus even with a very large study, no effect would have been detected. However, the response was clearly better in those believing they got LSD vs those believing they got placebo.’ This observation indicates that the perceived benefits of microdosing might largely stem from psychological expectations.
Considerations for Future Research
The study’s findings do not definitively rule out the potential benefits of microdosing for other conditions, but they suggest a strong placebo effect at play for ADHD symptoms. Liechti emphasized that rigorous controlled trials are essential to uncover the true efficacy of microdosing for various disorders.
In summary, the clinical trial raises significant questions about the efficacy of LSD microdosing for ADHD. While psychological beliefs appear to play a crucial role in perceived symptom relief, further research is needed to explore the potential of microdosing in treating other mental health conditions.
Comments are closed